Annuncio • Aug 12
Curaleaf Holdings, Inc. (TSX:CURA) proposed to acquire Aurora Cannabis Inc. (TSX:ACB) for approximately $270 million. Curaleaf Holdings, Inc. (TSX:CURA) proposed to acquire Aurora Cannabis Inc. (TSX:ACB) for approximately $270 million on August 11, 2026. The Offer will provide Aurora shareholders with total implied consideration of US$4.00 per share, comprised of 0.3463 Curaleaf Shares, plus US$0.75 cash, for each Aurora Share. Based on Aurora's 30-day Volume Weighted Average Price of US$2.75, the Offer Consideration implies a premium of 45% over the 30-day VWAP. Excluding the value of the cash and cash equivalents that Aurora has on its balance sheet, the Offer represents a premium of 110% premium to Aurora's 30-day VWAP. In the event of a substantial rise in the trading price of Curaleaf Shares before take-up under the Offer, the value of the Offer Consideration offered for each Aurora Share will be subject to a cap of US$5.00. In such case, Curaleaf will adjust the number of Curaleaf Shares offered as consideration in the Offer, such that the Offer Consideration for each Aurora Share is equal to the Cap Price. This Cap Price would represent a premium of 82% over the 30-day VWAP and a 197% premium above 30-day VWAP excluding the value of the cash and cash equivalents that Aurora has on its balance sheet. The Offer will be open for acceptance for a period of 105 days following formal commencement, unless the Offer is extended, accelerated or withdrawn in accordance with its terms. The Offer will be conditional upon certain conditions being satisfied or, where permitted, waived at or prior to the expiry of the Offer.
Canaccord Genuity Corp. acted as financial advisor for Curaleaf Holdings, Inc. Dentons Canada LLP acted as legal advisor for Curaleaf Holdings, Inc. Carson Proxy Advisors Ltd. acted as information agent for Curaleaf Holdings, Inc. New Risk • Aug 09
New minor risk - Profitability The company is currently unprofitable and not forecast to become profitable over the next 2 years. Trailing 12-month net loss: CA$52m Forecast net loss in 2 years: CA$2.4m This is considered a minor risk. Companies that are not profitable are more likely to be burning through cash and less likely to be well established. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. Without profits, the company is under pressure to grow significantly while potentially having to reduce costs and possibly needing to take on debt or raise capital to remain afloat. This is currently the only risk that has been identified for the company. Annuncio • Aug 06
Aurora Cannabis Inc. Provides Earnings Guidance for the Second Quarter of 2027 and Reiterates Earnings Guidance for the Full Year 2027 Aurora Cannabis Inc. provided earnings guidance for the second quarter of 2027 and reiterated earnings guidance for the full year 2027. For the quarter, the company expects revenue to be sequentially higher than in the fiscal first quarter.
For the full year, the company's reiterated outlook now capitalizes on the strategic decisions taken to exit the low margin Canadian Consumer and Plant Propagation businesses, which will allow the Company to reallocate resources to focus exclusively on global medical cannabis. The company believes this is their highest return and growth opportunity to create shareholder value. Over the next few quarters, the company is purposely investing in the international business through strategic sales initiatives and EU-GMP capacity expansion to support growth in the most profitable markets. This includes the new wholly owned subsidiary, Safari Flower Company, a trusted cultivator and manufacturer of high-quality medical cannabis, which provides incremental capacity to support further revenue growth in the key high margin international markets. These investments support the goal of driving the business to new records for revenue and generate sustained returns for the shareholders in the long term. Reported Earnings • Aug 05
First quarter 2027 earnings released: CA$0.07 loss per share (vs CA$0.26 loss in 1Q 2026) First quarter 2027 results: CA$0.07 loss per share (improved from CA$0.26 loss in 1Q 2026). Revenue: CA$67.6m (down 31% from 1Q 2026). Net loss: CA$4.03m (loss narrowed 73% from 1Q 2026). Revenue is forecast to grow 6.4% p.a. on average during the next 3 years, compared to a 9.2% growth forecast for the Pharmaceuticals industry in the US. Over the last 3 years on average, earnings per share has increased by 75% per year but the company’s share price has fallen by 18% per year, which means it is significantly lagging earnings. Annuncio • Jul 23
Aurora Cannabis Inc. to Report Q1, 2027 Results on Aug 05, 2026 Aurora Cannabis Inc. announced that they will report Q1, 2027 results Pre-Market on Aug 05, 2026 New Risk • Jun 30
New minor risk - Profitability The company is currently unprofitable and not forecast to become profitable over the next 2 years. Trailing 12-month net loss: CA$59m Forecast net loss in 2 years: CA$3.0m This is considered a minor risk. Companies that are not profitable are more likely to be burning through cash and less likely to be well established. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. Without profits, the company is under pressure to grow significantly while potentially having to reduce costs and possibly needing to take on debt or raise capital to remain afloat. This is currently the only risk that has been identified for the company. Reported Earnings • Jun 16
Full year 2026 earnings: EPS and revenues miss analyst expectations Full year 2026 results: CA$1.03 loss per share (down from CA$0.49 profit in FY 2025). Revenue: CA$320.6m (up 11% from FY 2025). Net loss: CA$58.6m (down 317% from profit in FY 2025). Revenue missed analyst estimates by 10%. Earnings per share (EPS) also missed analyst estimates by 121%. Revenue is forecast to grow 5.5% p.a. on average during the next 3 years, compared to a 8.9% growth forecast for the Pharmaceuticals industry in the US. Over the last 3 years on average, earnings per share has increased by 123% per year but the company’s share price has fallen by 19% per year, which means it is significantly lagging earnings. Annuncio • Jun 13
Aurora Cannabis Inc. Reports Impairment of Property, Plant and Equipment for the Fourth Quarter Ended March 31, 2026 Aurora Cannabis Inc. reported impairment of property, plant and equipment for the fourth quarter ended March 31, 2026. For the quarter, the company reported Impairment of property, plant and equipment of $2,246,000. Annuncio • Jun 12
Aurora Cannabis Inc. Provides Earnings Guidance for 2027 Aurora Cannabis Inc. provided earnings guidance for 2027. Outlook reflects the strategic changes they have made in exiting low margin Canadian Consumer and Plant Propagation businesses, which will allow the Company to reallocate resources to focus on global medical cannabis. They believe this is highest return opportunity to create value. Over the next few quarters, they are purposely investing in international business through strategic sales initiatives and EU GMP capacity expansion to support growth in most profitable markets. These efforts are expected to help offset the impact of margin reductions in Canadian medical business, following the reduction in government reimbursed pricing, effective April 1, 2026. Total Net Revenue is expected to decline and be more in line with Cannabis Net Revenue results in fiscal year 2025, following the changes in Canadian medical partially offset by international growth, driven by Germany and Poland. Annuncio • May 28
Aurora Cannabis Inc. to Report Q4, 2026 Results on Jun 11, 2026 Aurora Cannabis Inc. announced that they will report Q4, 2026 results Pre-Market on Jun 11, 2026 Annuncio • May 22
Aurora Cannabis Inc., Annual General Meeting, Aug 07, 2026 Aurora Cannabis Inc., Annual General Meeting, Aug 07, 2026. New Risk • May 12
New minor risk - Profitability The company is currently unprofitable and not forecast to become profitable over the next year. Trailing 12-month net loss: CA$84m Forecast net loss in 1 year: CA$33m This is considered a minor risk. Companies that are not profitable are more likely to be burning through cash and less likely to be well established. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. Without profits, the company is under pressure to grow significantly while potentially having to reduce costs and possibly needing to take on debt or raise capital to remain afloat. This is currently the only risk that has been identified for the company. Annuncio • Apr 17
Aurora Cannabis Inc. (TSX:ACB) acquired Safari Flower Co. for CAD 28.8 million. Aurora Cannabis Inc. (TSX:ACB) acquired Safari Flower Co. for CAD 28.8 million on April 14, 2026. The consideration for the transaction consists of CAD 15 million in cash, subject to customary adjustments post-closing, issuance of 2.4 million Aurora common shares, and CAD 2 million that is contingent on satisfaction of certain conditions.
The transaction is expected to be accretive.
Aurora Cannabis Inc. (TSX:ACB) completed the acquisition of Safari Flower Co. on April 14, 2026. Annuncio • Feb 11
Aurora Advances Global Medical Growth Strategy with Portfolio Expansion in Australia & New Zealand Aurora Cannabis Inc. is expanding its Aurora medical portfolio in Australia and New Zealand, delivering patients and prescribers enhanced choice, reliable quality, and easier access to science-backed products. The expansion underscores the company's ongoing dedication to meeting the unique needs of patients and healthcare professionals in the region, reflecting Aurora's strategic focus on long-term global growth. The expansion in New Zealand this month includes two new THC flower products - Big Wave, Night Ride, as well as the balanced strain, Half Moon™ coming soon in first quarter of fiscal year27. The brand will also debut four new resin cartridges in Australia this month including, Chemango Kush, Cosmic Cream, Lunar Express, and Soul Train Haze. Each new product is derived from Aurora's proprietary genetics, and manufactured at the company's leading EU-GMP and TGA-GMP certified facilities in Canada, ensuring the highest standards of quality and safety. New Zealand Launches: Big Wave™ - Flower, Hybrid, THC 26%, CBD; Night Ride™ - Flower, Indica, THC 29%, CBD; Half Moon™ - Flower, hybrid, THC 9%, CBD; Australia Launches: Chemango™ Kush - Resin Cartridge, Indica, THC 780mg/g, CBD. The Company cautions that the list of risks, uncertainties and other factors described in the AIF is not exhaustive and other factors could also adversely affect its results. Reported Earnings • Feb 05
Third quarter 2026 earnings released: EPS: CA$0.03 (vs CA$0.57 in 3Q 2025) Third quarter 2026 results: EPS: CA$0.03 (down from CA$0.57 in 3Q 2025). Revenue: CA$94.2m (up 6.8% from 3Q 2025). Net income: CA$1.98m (down 94% from 3Q 2025). Profit margin: 2.1% (down from 36% in 3Q 2025). Revenue is forecast to grow 6.4% p.a. on average during the next 3 years, compared to a 8.8% growth forecast for the Pharmaceuticals industry in the US. Over the last 3 years on average, earnings per share has increased by 143% per year but the company’s share price has fallen by 27% per year, which means it is significantly lagging earnings. Annuncio • Feb 04
Aurora Cannabis Inc. has filed a Follow-on Equity Offering in the amount of $100 million. Aurora Cannabis Inc. has filed a Follow-on Equity Offering in the amount of $100 million.
Security Name: Common Shares
Security Type: Common Stock
Transaction Features: At the Market Offering Annuncio • Jan 22
Aurora Cannabis Inc. to Report Q3, 2026 Results on Feb 04, 2026 Aurora Cannabis Inc. announced that they will report Q3, 2026 results at 9:30 AM, US Eastern Standard Time on Feb 04, 2026 Annuncio • Jan 14
Aurora Cannabis Inc. Announces Significant Progress in powdery mildew Disease Resistance Research Aurora Cannabis Inc. announced significant progress in its powdery mildew (PM) resistance research, nearly one year after the company's breakthrough discovery of a novel source of genetic resistance against powdery mildew, PM2. Since the initial discovery, Aurora has performed multiple rounds of crosses to transfer PM2 resistance into elite breeding lines. The research involves testing in breeding populations through controlled infection trials with high disease pressure, validating the durability and effectiveness of PM2 resistance. These trials are done to ensure that disease resistance is integrated into high-performing genetics without compromising quality traits, that are critical for patients and consumers globally. The company has recently shared its research at leading scientific and industry conferences, including the Plant & Animal Genome Conference, the Canadian Society for Horticultural Science & Canadian Society of Agronomy 2025 Conference, the 4th Annual Cannabis Scientific Symposium at the McGill Research Centre for Cannabis, and the PhotoX Conference. The proprietary genetic marker technology behind PM2 was developed by scientists at Aurora Coast, the company's world-class research and development facility, and builds from Aurora's previous collaboration with researchers at the University of British Columbia and research funding from Genome British Columbia. Should the production trials be successful, the company will look to commercialize PM-resistance cultivars later this year, which will protect plant health, reduce operational costs and improve product quality. As a global medical cannabis company enabled by science, Aurora continues to push the boundaries of cannabis science. By integrating advanced breeding techniques with rigorous research, Aurora is setting new standards for quality and efficiency, all while creating a strong production network to support existing and future markets. This intellectual property is currently patent pending in Canada, United States, Europe, Australia, New Zealand, and Israel. Reported Earnings • Nov 06
Second quarter 2026 earnings released: CA$0.91 loss per share (vs CA$0.048 profit in 2Q 2025) Second quarter 2026 results: CA$0.91 loss per share (down from CA$0.048 profit in 2Q 2025). Revenue: CA$90.4m (up 11% from 2Q 2025). Net loss: CA$51.6m (down CA$54.2m from profit in 2Q 2025). Revenue is forecast to grow 6.6% p.a. on average during the next 3 years, compared to a 8.9% growth forecast for the Pharmaceuticals industry in the US. Over the last 3 years on average, earnings per share has increased by 140% per year but the company’s share price has fallen by 31% per year, which means it is significantly lagging earnings. Annuncio • Oct 23
Aurora Cannabis Inc. to Report Q2, 2026 Results on Nov 05, 2025 Aurora Cannabis Inc. announced that they will report Q2, 2026 results Pre-Market on Nov 05, 2025 Annuncio • Aug 14
Aurora Cannabis Inc. Announces Executive Changes Aurora Cannabis Inc. announced that Theresa Firestone resigned from Aurora's Board of Directors effective August 31, 2025. Ms. Firestone was first appointed to the Aurora Board in 2021 and most recently served as Chair of the Human Resources and Compensation Committee (the "HRCC"). Immediately following the Meeting, and in addition to ratifying Michael Singer as the new Lead Independent Director, the Board has appointed Michael Singer to the role of Chair of the HRCC. New Risk • Aug 11
New minor risk - Share price stability The company's share price has been volatile over the past 3 months. It is more volatile than 75% of American stocks, typically moving 11% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. This is currently the only risk that has been identified for the company. Annuncio • Aug 08
Aurora Cannabis Inc. Provides Consolidated Earnings Guidance for the Second Quarter of 2026 Aurora Cannabis Inc. provided consolidated earnings guidance for the second quarter of 2026. for the quarter, the company expects net revenue increase year over year, driven primarily by 8% to 12% growth in its Global Medical Cannabis segment. Reported Earnings • Aug 06
First quarter 2026 earnings released: CA$0.26 loss per share (vs CA$0.12 profit in 1Q 2025) First quarter 2026 results: CA$0.26 loss per share (down from CA$0.12 profit in 1Q 2025). Revenue: CA$98.0m (up 18% from 1Q 2025). Net loss: CA$14.7m (down 337% from profit in 1Q 2025). Revenue is forecast to grow 7.3% p.a. on average during the next 3 years, compared to a 8.7% growth forecast for the Pharmaceuticals industry in the US. Over the last 3 years on average, earnings per share has increased by 131% per year but the company’s share price has fallen by 37% per year, which means it is significantly lagging earnings. Annuncio • Jul 24
Aurora Cannabis Inc. to Report Q1, 2026 Results on Aug 06, 2025 Aurora Cannabis Inc. announced that they will report Q1, 2026 results Pre-Market on Aug 06, 2025 Annuncio • Jun 26
Aurora Expands Patient Access to Medical Cannabis in Canada with Extended Compassionate Pricing Program Aurora Cannabis Inc. have recently expanded eligibility of their medical compassionate pricing program in Canada. As part of the company's ongoing commitment to making medical cannabis more accessible to patients, the yearly income eligibility of the program has increased from $40,000 to $60,000 for Aurora patients through AuroraMedical.com. The changes to the compassionate pricing program are available alongside new medical cannabis products, including: Aurora | Mediora Minis - Cannatonic CBD Flower, Sativa (10mg); Daily Special | Sativa J's - THC Pre-Rolls, Sativa (7 x 0.3g); WMMC | Seasonal Stash Petro Biscuit - THC Flower, Indica (10mg). In addition to the compassionate pricing program, Aurora offers resources to seniors, pediatric patients, veterans, first responders, and others seeking care through medical cannabis. Patients can visit for more information and to connect with the Aurora client care team for further support. New Risk • Jun 22
New minor risk - Earnings quality The company has large one-off items impacting its financial results. One-off items were 34% of the size of the rest of the company's trailing 12-month earnings before tax. This is considered a minor risk. One-off items are incomes or expenses that the company does not expect to repeat in future periods. Examples include profits from the sale of a business or expenses from a restructuring or legal settlements. If the company's reported statutory earnings include a large proportion of one-off items it means they may be an unreliable indicator of its true business performance as the earnings were skewed by these incomes or expenses. This is currently the only risk that has been identified for the company. Reported Earnings • Jun 18
Third quarter 2025 earnings released: EPS: CA$0.57 (vs CA$0.34 loss in 3Q 2024) Third quarter 2025 results: EPS: CA$0.57 (up from CA$0.34 loss in 3Q 2024). Revenue: CA$88.2m (up 37% from 3Q 2024). Net income: CA$31.6m (up CA$47.5m from 3Q 2024). Profit margin: 36% (up from net loss in 3Q 2024). Revenue is forecast to grow 11% p.a. on average during the next 4 years, compared to a 8.5% growth forecast for the Pharmaceuticals industry in the US. Over the last 3 years on average, earnings per share has increased by 92% per year but the company’s share price has fallen by 29% per year, which means it is significantly lagging earnings. Valuation Update With 7 Day Price Move • Jun 18
Investor sentiment deteriorates as stock falls 23% After last week's 23% share price decline to US$4.68, the stock trades at a forward P/E ratio of 24x. Average trailing P/E is 18x in the Pharmaceuticals industry in the US. Total loss to shareholders of 64% over the past three years. Annuncio • Jun 05
Aurora Cannabis Inc. Expands Medical Cannabis Offerings in Australia with the Launch of IndiMed TEMPO 22 Aurora Cannabis Inc. has expanded their popular IndiMed brand with the launch of IndiMed TEMPO 22, available through the company's subsidiary, MedReleaf Australia. With the same consistent quality and reliable supply, this new 22% THC potency creates a greater range of treatment options available to prescribers. IndiMed remains one of the most prescribed medical cannabis brands for patients in Australia. The two new Cultivars available include: IndiMed TEM PO 22 | Lemon Laser - Sativa, 22% THC, IndiMed TEMPO22 | Pickled Petrol - Indica, 22% THC, Aurora's continued focus on international growth and deep commitment to providing patients with innovative products and expanded access enables the company to maintain its global leadership position. MedReleaf Australia, a wholly owned subsidiary of Aurora, is committed to quality and proudly meeting all TGA-GMP standards. Annuncio • Jun 04
Aurora Cannabis Inc. to Report Q4, 2025 Results on Jun 18, 2025 Aurora Cannabis Inc. announced that they will report Q4, 2025 results Pre-Market on Jun 18, 2025 Annuncio • May 26
Aurora Cannabis Inc., Annual General Meeting, Aug 08, 2025 Aurora Cannabis Inc., Annual General Meeting, Aug 08, 2025. New Risk • Apr 24
New major risk - Share price stability The company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of American stocks, typically moving 17% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (17% average weekly change). Earnings are forecast to decline by an average of 31% per year for the foreseeable future. Minor Risks Large one-off items impacting financial results. Significant insider selling over the past 3 months (US$87k sold). Annuncio • Apr 15
Aurora Cannabis Introduces the Company's First Inhalable Resin Cartridges for Patients in the United Kingdom Aurora Cannabis Inc. has announced the availability of medical cannabis concentrates to patients in the United Kingdom (UK). This launch marks the company's meaningful step in offering its proprietary cultivar-specific inhalable cannabis extracts in the UK market. These products are available to patients in Canada and Australia and this launch reinforces Aurora's commitment to expanding patient access to an even greater variety of high-quality, premium medical cannabis globally. The two novel cultivar-specific Aurora 1.2g resin cartridges have been developed from two highly sought-after proprietary cultivars: Sourdough (indica) and Electric Honeydew (sativa). The inhalation method of these cartridges offers an ideal solution for fast and controlled delivery of medical cannabis. Key benefits of cannabis inhalers include: Exceptional Flavour Profiles: Connected to popular flower products, these strain-specific cartridges use high-quality terpenes and pure extracts to deliver rich and authentic flavours; High Potency: Ensures a powerful, consistent, controllable experience with each dose; Safety and Quality: Manufactured in facilities, adhering to strict TGA-GMP quality control and safety standards. These cartridges contain no additives, representing the pinnacle of cannabis purity; User-Friendly Design: Easy to use, making it a convenient, portable and discreet choice for patients. Aurora's portfolio of cannabis products is available nationwide for cannabis retailers to offer. Patients may contact their clinic for further information or consult their doctor. Annuncio • Mar 20
Aurora Cannabis Inc. Announces the Discovery of a Novel Source of Genetic Resistance Against Powdery Mildew, PM2 Aurora Cannabis Inc. announced the Company's discovery of a novel source of genetic resistance against powdery mildew, PM2, that provides strong protection against this pathogen in cannabis sativa. The development of this proprietary genetic marker technology, which is now in use in Aurora's breeding program, is set to produce powdery mildew resistant cultivars that will be explored for commercial launch this year. In the peer reviewed research lead by Jose Celedon, Principal Scientist of Breeding and Genetics at Aurora, in collaboration with researchers at The University of British Columbia, it is noted that, " breeding genetic resistance to economically important crop diseases is the most sustainable strategy for disease management and enhancing agricultural and horticultural productivity, particularly where the application of synthetic pesticides is prohibited" (Seifi, et al.) The discovery of PM2 will further the company's mission to enhance the biosecurity of production facilities, reduce production costs, and improve product quality. As a global medical cannabis company enabled by science, Aurora's dedication to scientific research and innovation has led to remarkable advancements, notably boosting potency and yield. These improvements have overall reduced costs and increased efficiency. This cutting-edge genetic research and development differentiates Aurora from others in the industry, as it aims to surpass traditional breeding limitations, leading to advanced cultivation methods and new market opportunities worldwide. New Risk • Mar 19
New major risk - Revenue and earnings growth Earnings are forecast to decline by an average of 31% per year for the foreseeable future. This is considered a major risk. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. If profits are expected to decline, then in most cases the share price will decline over time as well. In addition, if the company pays dividends it will also likely need to reduce or cut them, striking a dual blow to total shareholder returns. Currently, the following risks have been identified for the company: Major Risk Earnings are forecast to decline by an average of 31% per year for the foreseeable future. Minor Risks Share price has been volatile over the past 3 months (16% average weekly change). Large one-off items impacting financial results. Significant insider selling over the past 3 months (US$87k sold). Annuncio • Feb 21
Aurora Cannabis Inc. Expands Medical Cannabis Pastille Offerings in Australia Aurora Cannabis Inc. has announced the company's extended pastille offerings in Australia. This expansion marks another meaningful step in Aurora's deep commitment to offering patients a diverse range of high-quality, premium medical cannabis products to meet their various needs and interests. Medical cannabis pastilles offer several key benefits, including easy oral intake. The prolonged effects provide long-lasting and extended relief after digestion. Pastilles also come in an accessible format that is discrete, portable, and convenient. The pastilles that are now available in Australia include: Aurora Pastilles - 10mg THC Pomegranate Berry (30 pack) Aurora Pastilles - 10:10 Balanced Pineapple (30 pack) Aurora Pastille - 25mg CBD Acai Berry (30 pack) Aurora maintains its position as the largest global medical cannabis company operating in nationally legal markets. The company has a robust innovation pipeline planned for global introduction over the course of the coming months, bringing variety and new options to patients. Recent Insider Transactions • Feb 19
Insider recently sold US$87k worth of stock On the 12th of February, Andre Jerome sold around 13k shares on-market at roughly US$6.50 per share. This transaction amounted to 58% of their direct individual holding at the time of the trade. This was the largest sale by an insider in the last 3 months. This was the only on-market transaction from insiders over the last 12 months. Valuation Update With 7 Day Price Move • Feb 12
Investor sentiment improves as stock rises 18% After last week's 18% share price gain to US$6.33, the stock trades at a forward P/E ratio of 24x. Average trailing P/E is 18x in the Pharmaceuticals industry in the US. Total loss to shareholders of 87% over the past three years. Annuncio • Feb 07
Aurora Cannabis Inc. Reports Unaudited Consolidated Impairment of Property, Plant and Equipment for the Third Quarter Ended December 31, 2024 Aurora Cannabis Inc. reported unaudited consolidated impairment of property, plant and equipment for the third quarter ended December 31, 2024. For the quarter, the company reported impairment of property, plant and equipment of CAD 567,000. Reported Earnings • Feb 05
Third quarter 2025 earnings released: EPS: CA$0.57 (vs CA$0.51 loss in 3Q 2024) Third quarter 2025 results: EPS: CA$0.57 (up from CA$0.51 loss in 3Q 2024). Revenue: CA$88.2m (up 37% from 3Q 2024). Net income: CA$31.6m (up CA$55.7m from 3Q 2024). Profit margin: 36% (up from net loss in 3Q 2024). Revenue is forecast to grow 9.9% p.a. on average during the next 3 years, compared to a 9.1% growth forecast for the Pharmaceuticals industry in the US. Over the last 3 years on average, earnings per share has increased by 92% per year but the company’s share price has fallen by 51% per year, which means it is significantly lagging earnings. Board Change • Feb 02
Insufficient new directors There is 1 new director who has joined the board in the last 3 years. The company's board is composed of: 1 new director. 5 experienced directors. 1 highly experienced director. Independent Director Rajesh Uttamchandani was the last director to join the board, commencing their role in 2024. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model. Annuncio • Jan 23
Aurora Cannabis Inc. to Report Q3, 2025 Results on Feb 05, 2025 Aurora Cannabis Inc. announced that they will report Q3, 2025 results at 9:30 AM, US Eastern Standard Time on Feb 05, 2025 Annuncio • Nov 21
Aurora Cannabis Inc. Expands Innovative Recreational Product Portfolio Aurora Cannabis Inc. announced its latest lineup of innovations from Greybeard, San Rafael '71 and Tasty's brands. With a continued focus on premium, science-driven offerings, this expanded lineup represents Aurora's commitment to delivering exceptional high quality, cutting-edge and diverse options for Canadian cannabis consumers. Aurora boasts a leading portfolio of brands that Canadians know and love, including Greybeard, San Rafael ' 71 and Tasty's. Following Tasty's inaugural year in the Canadian adult market, the brand leaned into valuable consumer insights to develop. The new offerings reinforce Tasty's commitment to quality, creativity, and an unforgettable cannabis experience. The latest products available across Canada include the following: Greybeard | Banana GasPure Live Resin Vape, awakens senses with authentic notes of gassy bananas on the inhale and a savoury, umami finish on the exhale. Greybeard | Country Lemon Terp Slush (1g); live resin extract featuring a bright, golden hue and a smooth, suugary texture. Greybeard | Critical Diesel Pre-Rolls (3 x 0.5g); crafted from 100% whole milled bud, not trim, these pre-rolls are an effortless way to experience Greybeard's latest craft sativa - known for its unique blend of cherry, grape, strawberry, vanilla and gas aromas. San Rafael '71 | 20 Pack Pre-Rolls (20 x 0.5g); made in response to the growing demand for bulk pre-roll options; perfect for those who appreciate consistency and value. Tasty's | Mango Diamond Infused Pre-Rolls, Indica (3 x 0.5 g), infused with ultra- powerful THC-A diamonds, with a burst of tangy, sun-kissed mango flavours enhanced by botanical terpenes. Tasty's | Honeydew Diamond Infused Pre- Rolls, Sativa (3 x 0.5G), infused with THC-A diamonds, with ripe, refreshing honeydew flavour. Tasty's | Melon Diamond Infused Pre-Rolling Pre-Rolls, Sativa (3x 0.5g), created with THC-A diamonds and refreshing sweet melon flavours. Tasty's | Grape 510 Vape (1.2g), offers an unbeatable combination of taste and 1000mg of THC to deliver a tangling sweetness with subtle tanginess. Aurora's portfolio of cannabis products are made available nationwide for cannabis retailers to offer. New Risk • Nov 12
New minor risk - Profitability The company is currently unprofitable and not forecast to become profitable over the next year. Trailing 12-month net loss: CA$30m Forecast net loss in 1 year: CA$409k This is considered a minor risk. Companies that are not profitable are more likely to be burning through cash and less likely to be well established. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. Without profits, the company is under pressure to grow significantly while potentially having to reduce costs and possibly needing to take on debt or raise capital to remain afloat. Currently, the following risks have been identified for the company: Minor Risks Currently unprofitable and not forecast to become profitable next year (CA$409k net loss next year). Shareholders have been diluted in the past year (15% increase in shares outstanding). Breakeven Date Change • Nov 08
Forecast to breakeven in 2026 The 6 analysts covering Aurora Cannabis expect the company to break even for the first time. New consensus forecast suggests losses will reduce by 75% to 2025. The company is expected to make a profit of CA$2.59m in 2026. Average annual earnings growth of 81% is required to achieve expected profit on schedule. Annuncio • Nov 08
Aurora Cannabis Inc. Announces Notice of Proposed Settlement of Class Action Involving All Persons and Entities Who Purchased Aurora Cannabis Inc. Common Stock Between October 23, 2018 and February 28, 2020, Inclusive Aurora Cannabis Inc. announces that hearing will be held on January 28, 2025, at 2:00 p.m., before the Honorable James B. Clark, III at the United States District Court, District of New Jersey, Frank R. Lautenberg Post Office & U.S. Courthouse, 2 Federal Square, Newark, New Jersey 07102, to determine whether: (1) the proposed settlement (the "Settlement") of the above-captioned Litigation as set in the Stipulation of Settlement ("Stipulation")[1] for $8.05 million in cash should be approved by the Court as fair, reasonable, and adequate; (2) the Judgment as provided under the Stipulation should be entered dismissing the Litigation with prejudice; (3) to award Lead Plaintiffs' Counsel attorneys' fees and expenses out of the Settlement Fund (as defined in the Notice of Pendency and Proposed Settlement of Class Action ("Notice"), which is discussed below) and, if so, in what amounts; (4) to reimburse Lead Plaintiffs for their time and expenses in connection with their representation of the Settlement Class and, if so, in what amounts; and (5) the Plan of Allocation should be approved by the Court as fair, reasonable, and adequate. To share in the distribution of the Net Settlement Fund, one must establish rights by submitting a Proof of Claim and Release form ("Proof of Claim") by mail (postmarked no later than February 27, 2025) or electronically via the website (no later than February 27, 2025). Reported Earnings • Nov 07
Second quarter 2025 earnings released: EPS: CA$0.05 (vs CA$0.048 in 2Q 2024) Second quarter 2025 results: EPS: CA$0.05 (up from CA$0.048 in 2Q 2024). Revenue: CA$81.1m (up 28% from 2Q 2024). Net income: CA$2.60m (up 40% from 2Q 2024). Profit margin: 3.2% (up from 2.9% in 2Q 2024). Revenue is forecast to grow 9.8% p.a. on average during the next 3 years, compared to a 10% growth forecast for the Pharmaceuticals industry in the US. Over the last 3 years on average, earnings per share has increased by 73% per year but the company’s share price has fallen by 59% per year, which means it is significantly lagging earnings. Annuncio • Oct 25
Aurora Cannabis Inc. to Report Q2, 2025 Results on Nov 06, 2024 Aurora Cannabis Inc. announced that they will report Q2, 2025 results Pre-Market on Nov 06, 2024 Annuncio • Sep 21
Aurora Cannabis Inc. Announces Board Changes and Changes to Board Committee Compositions Aurora Cannabis Inc. announced the appointments of CEO Miguel Martin to the additional role of executive chairman and outgoing chairman Ron Funk as lead independent director. Both are backed by unanimous votes by the company's board of director and are effective immediately. Martin has led Aurora as CEO and a director since 2020, driving the company's financial recovery and successful business transformation. Changes to Board Committee Compositions: Michael Singer, who previously acted as executive chairman and interim CEO, was appointed to the Audit Committee and the Human Resource and Compensation Committee. Rajesh Uttamchandani was appointed to the HRCC and the Nominating and Corporate Governance Committee. Reported Earnings • Aug 08
First quarter 2025 earnings: EPS and revenues exceed analyst expectations First quarter 2025 results: EPS: CA$0.12 (up from CA$0.59 loss in 1Q 2024). Revenue: CA$83.4m (up 11% from 1Q 2024). Net income: CA$6.22m (up CA$27.0m from 1Q 2024). Profit margin: 7.5% (up from net loss in 1Q 2024). Revenue exceeded analyst estimates by 7.6%. Earnings per share (EPS) also surpassed analyst estimates. Revenue is forecast to grow 12% p.a. on average during the next 3 years, compared to a 9.5% growth forecast for the Pharmaceuticals industry in the US. Over the last 3 years on average, earnings per share has increased by 64% per year but the company’s share price has fallen by 54% per year, which means it is significantly lagging earnings. Annuncio • Jul 29
Aurora Cannabis Inc. to Report Q1, 2025 Results on Aug 07, 2024 Aurora Cannabis Inc. announced that they will report Q1, 2025 results Pre-Market on Aug 07, 2024 New Risk • Jun 27
New minor risk - Profitability The company is currently unprofitable and not forecast to become profitable over the next 3 years. Trailing 12-month net loss: CA$55m Forecast net loss in 3 years: CA$6.0m This is considered a minor risk. Companies that are not profitable are more likely to be burning through cash and less likely to be well established. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. Without profits, the company is under pressure to grow significantly while potentially having to reduce costs and possibly needing to take on debt or raise capital to remain afloat. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (23% average weekly change). Shareholders have been substantially diluted in the past year (54% increase in shares outstanding). Minor Risk Currently unprofitable and not forecast to become profitable over next 3 years (CA$6.0m net loss in 3 years). Reported Earnings • Jun 21
Full year 2024 earnings released: CA$1.28 loss per share (vs CA$8.22 loss in FY 2023) Full year 2024 results: CA$1.28 loss per share (improved from CA$8.22 loss in FY 2023). Revenue: CA$270.3m (up 16% from FY 2023). Net loss: CA$55.3m (loss narrowed 79% from FY 2023). Revenue is forecast to grow 14% p.a. on average during the next 3 years, compared to a 10% growth forecast for the Pharmaceuticals industry in the US. Over the last 3 years on average, earnings per share has increased by 80% per year but the company’s share price has fallen by 61% per year, which means it is significantly lagging earnings. Breakeven Date Change • Jun 21
Forecast breakeven date pushed back to 2027 The 6 analysts covering Aurora Cannabis previously expected the company to break even in 2026. New consensus forecast suggests losses will reduce by 91% per year to 2026. The company is expected to make a profit of CA$18.7m in 2027. Average annual earnings growth of 71% is required to achieve expected profit on schedule. Annuncio • May 16
Aurora Cannabis Inc. Appoints Rajesh Uttamchandani to its Board of Directors Aurora Cannabis Inc. announced the appointment of Rajesh Uttamchandani to the Company's Board of Directors, effective May 15, 2024. Mr. Uttamchandani joins the Board with notable expertise in strategy development, innovation, human capital and governance. His impressive career is characterized by executive level roles with leading businesses in emerging technology, FinTech, human capital consulting and global education. Most recently, he was the Chief People Officer for ApplyBoard. Previous roles include serving as Chief Operating Officer and Chief People Officer at MaRs Discovery District and Chief Human Resources Officer and Managing Director at Zafin. Mr. Uttamchandani brings to Aurora a wealth of experience as current and past Director for private and public organizations, including LifeSpeak, Ontario Cannabis Stores, Mackenzie Health, and several not-for-profit organizations. Mr. Uttamchandani holds several degrees and professional designations, including a Master of Industrial Relations and Human Resources from University of Toronto; a Juris Doctor from Osgoode Hall Law School; and an L.L.M in Employment and Labour, also from Osgoode Hall Law School. He is a holder of the Institute of Corporate Directors Director designation (ICD.D) and is a lawyer called to the Bar of Ontario. Annuncio • Apr 30
Aurora Cannabis Inc. in Conjunction with MedReleaf Australia, Announce Expansion of its Portfolio with Introduction of New Range of Premium Dried Cannabis Flower Products Aurora Cannabis Inc. in conjunction with MedReleaf Australia, announced the expansion of its portfolio with the introduction of a new range of premium dried cannabis flower products. Now available for doctors to prescribe to patients in Australia, the new products developed by Aurora and manufactured at its EU-GMP and TGA-GMP certified facility, will be distributed by MedReleaf Australia. The new dried flowers, including Black Jelly, Chemango Kush, and Moon Berry, are proprietary cultivars cultivated exclusively by Aurora. Vespera, a previously existing proprietary cultivar, is also set for relaunch under the Aurora brand. These products mark a significant step forward for MedReleaf Australia as they continue to expand their offerings under the Aurora brand. The dried flower products are available now in four 10g formats including: Aurora Moon Berry T9/C13 Balanced; Aurora Black Jelly T28/C1 Sativa; Aurora Chemango Kush T29/C1 Indica; and Aurora Vespera T1/C17 CBD. The expanded range of Aurora products caters to the market demand for more affordable options without compromising on quality. With a focus on sustainability, the 2.0 genetics employed in these cultivars ensure reliable large-scale cultivation to meet market demand while maintaining elevated quality standards. Furthermore, the MedReleaf Australia family of brands now focuses on three core brands - CraftPlant, offering a hand-crafted, premium range of products; Aurora, for innovative and affordable options; and IndiMed, providing a company-funded concession range. New Risk • Mar 23
New minor risk - Share price stability The company's share price has been volatile over the past 3 months. It is more volatile than 75% of American stocks, typically moving 12% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risks Earnings are forecast to decline by an average of 61% per year for the foreseeable future. High level of non-cash earnings (104% accrual ratio). Shareholders have been substantially diluted in the past year (59% increase in shares outstanding). Minor Risk Share price has been volatile over the past 3 months (12% average weekly change). Annuncio • Feb 20
Aurora Cannabis Inc. Announces CFO Changes Aurora Cannabis Inc. announced that Simona King, a former executive of Bristol Myers-Squibb, a leading multinational pharmaceutical company, has been appointed as Chief Financial Officer of the Company, effective February 21, 2024. Ms. King brings over 25 years of progressive finance leadership experience, with deep business knowledge and proven success with global and emerging organizations. She served nearly 20 years with Bristol Myers-Squibb, where she held increasingly senior finance roles and enabled the company's growth strategy. Glen Ibbott, current Chief Financial Officer, will be stepping down from his full-time role effective 20 February 2024, to pursue new opportunities. He will remain in an advisory role over the next few months to ensure a smooth transition of responsibilities to Simona. Ms. King brings deep financial expertise across corporate, operations and international business units. In recent years, she has spread her professional reach, joining fast moving public companies in emerging sectors, including biotech. She joins Aurora most recently as the CFO of a number of clinical stage biotechnology companies. Reported Earnings • Feb 14
Third quarter 2024 earnings: Revenues exceed analysts expectations while EPS lags behind Third quarter 2024 results: CA$0.051 loss per share (improved from CA$0.19 loss in 3Q 2023). Revenue: CA$64.4m (up 5.5% from 3Q 2023). Net loss: CA$24.2m (loss narrowed 60% from 3Q 2023). Revenue exceeded analyst estimates by 1.5%. Earnings per share (EPS) missed analyst estimates. Revenue is forecast to grow 12% p.a. on average during the next 3 years, compared to a 9.0% growth forecast for the Pharmaceuticals industry in the US. New Risk • Feb 11
New major risk - Shareholder dilution The company's shareholders have been substantially diluted in the past year. Increase in shares outstanding: 60% This is considered a major risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risk Shareholders have been substantially diluted in the past year (60% increase in shares outstanding). Minor Risk Currently unprofitable and not forecast to become profitable over next 3 years (CA$1.9m net loss in 3 years). New Risk • Feb 10
New minor risk - Profitability The company is currently unprofitable and not forecast to become profitable over the next 3 years. Trailing 12-month net loss: CA$1.7b Forecast net loss in 3 years: CA$2.8m This is considered a minor risk. Companies that are not profitable are more likely to be burning through cash and less likely to be well established. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. Without profits, the company is under pressure to grow significantly while potentially having to reduce costs and possibly needing to take on debt or raise capital to remain afloat. Currently, the following risks have been identified for the company: Minor Risks Currently unprofitable and not forecast to become profitable over next 3 years (CA$2.8m net loss in 3 years). Shareholders have been diluted in the past year (40% increase in shares outstanding). Annuncio • Feb 09
Aurora Cannabis Inc. (TSX:ACB) acquired remaining 90% stake in Indica Industries Pty Ltd for AUD 45 million. Aurora Cannabis Inc. (TSX:ACB) acquired remaining 90% stake in Indica Industries Pty Ltd for AUD 45 million on February 7, 2024.The consideration should be paid in approximately AUD$9.5 million in cash and the remainder by the issuance of Common Shares. The transaction is subject to customary adjustments.Aurora Cannabis Inc. (TSX:ACB) completed the acquisition of remaining 90% stake in Indica Industries Pty Ltd for AUD 45 million on February 7, 2024. Annuncio • Feb 08
Aurora Cannabis Inc. Provides Earnings Guidance for the Fourth Quarter of Fiscal 2024 Aurora Cannabis Inc. provided earnings guidance for the fourth quarter of fiscal 2024. For the quarter, company expects revenue from Canadian medical and consumer segments to be steady quarter over quarter, while Europe and Australia should provide modest growth in their regions and Revenue increases combined with ongoing cost control are expected to result in continued positive. Annuncio • Feb 01
Aurora Cannabis Inc. to Report Q3, 2024 Results on Feb 08, 2024 Aurora Cannabis Inc. announced that they will report Q3, 2024 results Pre-Market on Feb 08, 2024 Breakeven Date Change • Nov 12
Forecast to breakeven in 2026 The 8 analysts covering Aurora Cannabis expect the company to break even for the first time. New consensus forecast suggests the company will make a profit of CA$13.4m in 2026. Average annual earnings growth of 151% is required to achieve expected profit on schedule. New Risk • Nov 12
New major risk - Financial position The company has less than a year of cash runway based on its current free cash flow trend. Free cash flow: -CA$164m This is considered a major risk. With less than a year's worth of cash, the company will need to raise capital or take on debt unless its cash flows improve. This would dilute existing shareholders or increase balance sheet risk. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-CA$164m free cash flow). Share price has been highly volatile over the past 3 months (24% average weekly change). Minor Risk Shareholders have been diluted in the past year (46% increase in shares outstanding). Annuncio • Nov 11
Aurora Cannabis Inc. Provides Revenue Guidance for Third Quarter of Fiscal 2024 Aurora Cannabis Inc. Provided Revenue Guidance for third quarter of fiscal 2024. For the period, the company expects cannabis revenue to be largely similar to fiscal second quarter, 2024, with the geographical mix slightly weighted further towards the international medical segment. For plant propagation, company expect to see seasonally reduced revenues and gross profit in fiscal third quarter 2024 that will be consistent with fiscal second quarter 2024 and in line with historical performance. Annuncio • Oct 27
Aurora Cannabis Inc. to Report Q2, 2024 Results on Nov 09, 2023 Aurora Cannabis Inc. announced that they will report Q2, 2024 results After-Market on Nov 09, 2023 New Risk • Oct 05
New major risk - Shareholder dilution The company's shareholders have been substantially diluted in the past year. Increase in shares outstanding: 56% This is considered a major risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (23% average weekly change). Shareholders have been substantially diluted in the past year (56% increase in shares outstanding). Annuncio • Oct 05
Aurora Cannabis Inc. has completed a Follow-on Equity Offering in the amount of CAD 38.826875 million. Aurora Cannabis Inc. has completed a Follow-on Equity Offering in the amount of CAD 38.826875 million.
Security Name: Common Shares
Security Type: Common Stock
Securities Offered: 53,187,500
Price\Range: CAD 0.73
Discount Per Security: CAD 0.0365 New Risk • Aug 14
New major risk - Financial position The company has less than a year of cash runway based on its current free cash flow trend. Free cash flow: -CA$164m This is considered a major risk. With less than a year's worth of cash, the company will need to raise capital or take on debt unless its cash flows improve. This would dilute existing shareholders or increase balance sheet risk. Currently, the following risks have been identified for the company: Major Risk Less than 1 year of cash runway based on free cash flow trend (-CA$164m free cash flow). Minor Risk Shareholders have been diluted in the past year (27% increase in shares outstanding). Annuncio • Aug 11
Aurora Cannabis Inc. Provides Revenue Guidance for the Second Quarter of Fiscal Year 2024 Aurora Cannabis Inc. provided revenue guidance for the second quarter of fiscal year 2024. For the quarter, the company expects cannabis net revenue to be largely similar to fiscal first quarter 2024, with the geographical mix slightly weighted further towards the international medical segment. For plant propagation, the company expects to see seasonally reduced revenues in second quarter 2024 that will be in line with historical performance as 25% – 35% of revenues are normally earned in the second half of a calendar year. Annuncio • Jul 29
Aurora Cannabis Inc. to Report Q1, 2024 Results on Aug 10, 2023 Aurora Cannabis Inc. announced that they will report Q1, 2024 results After-Market on Aug 10, 2023 Annuncio • Jul 25
Bevo Farms Ltd acquired Medicine Hat, Alberta Aurora Sun Facility from Aurora Cannabis Inc. (TSX:ACB) for CAD 15 million. Bevo Farms Ltd acquired Medicine Hat, Alberta Aurora Sun Facility from Aurora Cannabis Inc. (TSX:ACB) for CAD 15 million on July 21, 2023. Up to CAD 15 million could be payable over time by Bevo Farms to Aurora in connection with the Aurora Sun Transaction, based on Bevo Farms successfully achieving certain financial milestones at the Aurora Sun Facility.
Bevo Farms Ltd completed the acquisition of Medicine Hat, Alberta Aurora Sun Facility from Aurora Cannabis Inc. (TSX:ACB) on July 21, 2023. Buying Opportunity • Jul 14
Now 21% undervalued after recent price drop Over the last 90 days, the stock is down 17%. The fair value is estimated to be US$0.67, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has declined by 11% over the last 3 years. Earnings per share has grown by 67%. Revenue is forecast to grow by 21% in 2 years. Earnings is forecast to grow by 96% in the next 2 years. Recent Insider Transactions • Jun 24
CEO & Director recently bought US$98k worth of stock On the 20th of June, Miguel Martin bought around 179k shares on-market at roughly US$0.55 per share. This transaction amounted to 92% of their direct individual holding at the time of the trade. This was the largest purchase by an insider in the last 3 months. This was Miguel's only on-market trade for the last 12 months. New Risk • Jun 23
New minor risk - Profitability The company is currently unprofitable and not forecast to become profitable over the next 3 years. Trailing 12-month net loss: CA$818m Forecast net loss in 3 years: CA$9.4m This is considered a minor risk. Companies that are not profitable are more likely to be burning through cash and less likely to be well established. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. Without profits, the company is under pressure to grow significantly while potentially having to reduce costs and possibly needing to take on debt or raise capital to remain afloat. Currently, the following risks have been identified for the company: Minor Risks Currently unprofitable and not forecast to become profitable over next 3 years (CA$9.4m net loss in 3 years). Shareholders have been diluted in the past year (19% increase in shares outstanding). Reported Earnings • Jun 16
Third quarter 2023 earnings released: CA$0.24 loss per share (vs CA$4.72 loss in 3Q 2022) Third quarter 2023 results: CA$0.24 loss per share (improved from CA$4.72 loss in 3Q 2022). Revenue: CA$64.0m (up 27% from 3Q 2022). Net loss: CA$82.0m (loss narrowed 92% from 3Q 2022). Revenue is forecast to grow 13% p.a. on average during the next 3 years, compared to a 6.2% growth forecast for the Pharmaceuticals industry in the US. Annuncio • Jun 09
Aurora Cannabis Inc. to Report Fiscal Year 2023 Results on Jun 14, 2023 Aurora Cannabis Inc. announced that they will report fiscal year 2023 results Pre-Market on Jun 14, 2023 Annuncio • Jun 07
Aurora Celebrates Summer with New Innovation Launching Across Canada Aurora Cannabis Inc. is launching a fresh lineup of innovative products, available to patients on Aurora Medical and consumers, at retailers across the country this summer. The company's ever-expanding portfolio includes new 1mg format, snackable edibles, premium resin vape carts with big, bold flavour, and a true-to-form signature hash. New flower products include Chemango Kush, an original strain from Occo, Aurora's esteemed breeding program, as well as 14g format extensions on popular strains, Moon Berry and Pink Diesel. In addition to leveraging Aurora's best-in-class genetics breeding and research program, the company has launched Aurora Lab, an exclusive experiential research and education program designed to strengthen two-way conversations with patients, retailers, budtenders and consumers. Through Aurora Lab, partners get behind-the-scenes access and sneak peeks at new products and formats, while invited patients get a chance to trial unreleased products in exchange for feedback. Insights gleaned from the program will be used to develop future products and inform Aurora's innovation pipeline. Annuncio • May 26
Aurora Cannabis Inc., Annual General Meeting, Aug 14, 2023 Aurora Cannabis Inc., Annual General Meeting, Aug 14, 2023. Breakeven Date Change • Mar 31
Forecast to breakeven in 2026 The 8 analysts covering Aurora Cannabis expect the company to break even for the first time. New consensus forecast suggests the company will make a profit of CA$1.50m in 2026. Average annual earnings growth of 45% is required to achieve expected profit on schedule. Annuncio • Feb 11
Aurora Cannabis Inc. Reports Impairment Changes for the Quarter Ended December 31, 2022 Aurora Cannabis Inc. reported impairment changes for the quarter ended December 31, 2022. For the quarter, the company reported impairment of property, plant and equipment of CAD 2,259,000 against CAD 4,281,000 a year ago. Reported Earnings • Feb 10
Second quarter 2023 earnings released Second quarter 2023 results: Revenue: CA$61.7m (up 1.8% from 2Q 2022). Net loss: CA$65.4m (loss narrowed 13% from 2Q 2022). Revenue is forecast to grow 22% p.a. on average during the next 6 years, compared to a 4.5% growth forecast for the Pharmaceuticals industry in the US. Annuncio • Jan 27
Aurora Cannabis Inc. to Report Q2, 2023 Results on Feb 09, 2023 Aurora Cannabis Inc. announced that they will report Q2, 2023 results After-Market on Feb 09, 2023 Annuncio • Jan 05
An Unknown buyer acquired Aurora Polaris facility from Aurora Cannabis Inc. for CAD15 million. An Unknown buyer acquired Aurora Polaris facility from Aurora Cannabis Inc. for CAD15 million on January 4, 2023.An Unknown buyer completed the acquisition of Aurora Polaris facility from Aurora Cannabis Inc. for CAD15 million on January 4, 2023. Buying Opportunity • Dec 28
Now 20% undervalued after recent price drop Over the last 90 days, the stock is down 32%. The fair value is estimated to be US$1.06, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has declined by 11% over the last 3 years. Earnings per share has grown by 39%. For the next 3 years, revenue is forecast to grow by 18% per annum. Earnings is also forecast to grow by 48% per annum over the same time period. Reported Earnings • Nov 16
First quarter 2023 earnings: EPS and revenues miss analyst expectations First quarter 2023 results: CA$0.17 loss per share (further deteriorated from CA$0.06 loss in 1Q 2022). Revenue: CA$49.3m (down 18% from 1Q 2022). Net loss: CA$51.6m (loss widened 334% from 1Q 2022). Revenue missed analyst estimates by 7.5%. Earnings per share (EPS) also missed analyst estimates by 21%. Revenue is forecast to grow 22% p.a. on average during the next 6 years, compared to a 3.8% growth forecast for the Pharmaceuticals industry in the US. Over the last 3 years on average, earnings per share has increased by 39% per year but the company’s share price has fallen by 62% per year, which means it is significantly lagging earnings. Breakeven Date Change • Nov 16
Forecast to breakeven in 2025 The 5 analysts covering Aurora Cannabis expect the company to break even for the first time. New consensus forecast suggests losses will reduce by 80% per year to 2024. The company is expected to make a profit of CA$32.0m in 2025. Average annual earnings growth of 47% is required to achieve expected profit on schedule. Reported Earnings • Nov 11
First quarter 2023 earnings released: CA$0.17 loss per share (vs CA$0.06 loss in 1Q 2022) First quarter 2023 results: CA$0.17 loss per share (further deteriorated from CA$0.06 loss in 1Q 2022). Revenue: CA$49.3m (down 18% from 1Q 2022). Net loss: CA$51.6m (loss widened 334% from 1Q 2022). Revenue is forecast to grow 25% p.a. on average during the next 6 years, compared to a 4.0% growth forecast for the Pharmaceuticals industry in the US. Reported Earnings • Sep 21
Full year 2022 earnings: Revenues in line with analyst expectations Full year 2022 results: Revenue: CA$221.3m (down 9.8% from FY 2021). Net loss: CA$1.72b (loss widened 148% from FY 2021). Revenue was in line with analyst estimates. Revenue is forecast to grow 15% p.a. on average during the next 3 years, compared to a 3.6% growth forecast for the Pharmaceuticals industry in the US.